Diffusion Pharmaceuticals is moving rapidly to evaluate trans sodium crocetinate (TSC)’s potential to address some of medicine’s most intractable and difficult-to-treat conditions that involve cellular oxygen deficiency, or hypoxia.
TSC has broad patent protection through to 2031 and a mechanism of action designed to address oxygen-deprivation in hypoxic tissues by enhancing oxygen diffusion through the blood and into the cells. The company is committed to uncovering TSC’s full potential across a range of disorders, including respiratory conditions such as COVID-19, stroke, glioblastoma multiforme (GBM) brain cancer, neurodegenerative diseases, and other conditions and diseases in which hypoxia is a critical factor which presents a significant obstacle for medical providers.
In addition to TSC, Diffusion owns the rights to DFN-529, a novel PI3K/Akt/mTOR pathway inhibitor that was previously in preclinical development in oncology, specifically for GBM, and for which two Phase 1 clinical trials have been completed for age-related macular degeneration. DFN-529 has shown activity in both in vitro and in vivo glioblastoma animal models and has been demonstrated to be orally bioavailable and capable of crossing the blood-brain barrier.